Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the isoindolone class of aromatic polycyclic compounds. It is primarily known as an experimental agent and has been studied for its activity as a cyclin-dependent kinase 2 (CDK2) inhibitor. CDK2 is involved in cell cycle regulation, and inhibition of this kinase can disrupt cancer cell proliferation, making this compound of interest in oncology research. The drug does not have an assigned CAS number or UNII and appears to be at the preclinical or early experimental stage with no approved therapeutic indications or commercial brand names identified[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-[(2-aminoethyl)amino]-6-fluoro-3-(1H-pyrrol-2-yl)benzo[cd]indol-2(1H)-one.